|Fastest Growing Market:||Asia-Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The central nervous system (CNS) stimulant drugs market is anticipated to register a CAGR of 4.3% during the forecast period.
With the increasing COVID-19 cases worldwide, healthcare services diverted all resources toward patients suffering from COVID-19 disease. Although COVID-19 severely affects the respiratory system, it has been reported to show effects on central and peripheral systems. Supply chain disruption, government-imposed lockdowns, and trade bans in several countries significantly impacted the central nervous system (CNS) stimulant drugs market. The COVID-19 pandemic has had three major effects on the global market for central nervous system stimulant drugs market, it has directly affected the production and demand of central nervous system (CNS) stimulants drugs; it has disrupted distribution channels, and it has had a financial impact on firms and financial markets.
Certain factors that are driving the market growth include CNS disorders like sleep apnea, narcolepsy, and attention-deficit hyperactivity disorder which have witnessed a significant rise in current years. For instance, according to the sleep foundation in 2022, sleep apnea is likely to affect between 2-9% of adults in the United States. According to the same source central sleep apnea has been observed to affect about 9% of adults above the age of 40 years. It was observed significantly in men than in women. The increasing incidence of CNS disorders will take the lead to the expansion of the global central nervous system stimulant drugs market. For instance, as per the research study published in National Center for Biotechnology Information in 2020, titled 'Prevalence of the major neurological disorders in a semi-urban community in northern Benin', the prevalence of neurological diseases was found to be 45.4%. More precisely, the prevalence of tension headaches was 26.9%, peripheral neuropathies 5.6%, epilepsy 1.9%, stroke 0.1%, and migraine 14.3%.
Scope of the Report
A central nervous system (CNS) stimulant is a type of drug that enhances the levels of specific compounds in the brain and encourages alertness, attention, energy, and physical activity. The central nervous system (CNS) stimulant drugs market is segmented By Product Type (Lisdexamfetamine, Dextroamphetamine, Methylphenidate HCl, and Other Product Type), Application (Attention Deficit Hyperactivity Disorder (ADHD), Sleeping Disorder, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
|By Poduct Type|
|Other Product Type|
|Attention Deficit Hyperactivity Disorder (ADHD)|
Key Market Trends
Attention-Deficit Hyperactivity Disorder Segment is Expected to Hold a Major Market Share in the Central Nervous System Stimulant Drugs Market
The attention-deficit hyperactivity disorder segment is expected to hold a significant market share in the central nervous system (CNS) stimulant drugs market over the forecast period. Factors such as the rising prevalence of attention-deficit hyperactivity disorder amongst children and adolescents and the easy availability of treatment drugs such as CNS stimulants are likely to propel the segment growth over the forecast period. For instance, as per the Centers for Disease Control and Prevention in 2021, the approximate number of children ever detected with attention-deficit/hyperactivity disorder (ADHD) was 6.1 million with a prevalence rate of 9.4%.
Additionally, as per the research study published in the Journal of Education and Health Promotion in 2021, Approximately 5% of kids around the world suffer from attention-deficit hyperactivity (ADHD). According to the same source, it was found the prevalence of 5.29% in Northern America, 12.3% in Southern America, 8.9% in Africa, the Middle East 2.5%, 4.8% in Australia, and Asia account for 4.2% prevalence of attention-deficit hyperactivity (ADHD).
To understand key trends, Download Sample Report
North America is Expected to Dominate the Central Nervous System Stimulant Drugs Market
Several clinical trials are ongoing in North America, especially in the United States. Among the total neurological disease clinical studies being conducted, worldwide, more than half are in the United States. In March 2021, United States President Biden signed the American Rescue Plan Act 2021. According to the act, a portion of spending is allotted to mental health services, further increasing the government activities toward neurological diseases. The rising burden of the disease and healthcare infrastructure and supportive government initiatives make North America a very attractive opportunity for industries.
According to the research study published in British Medical Journal in 2021, approximately 4.1 million United States adults reported prescriptions for CNS stimulants drugs. As per the same source it was reported that the growth rate of total number of prescriptions dispensed was approximately 96% and the major percentage increases occurred in adults aged 25 years and older. However, increase in abuse of CNS stimulants is expected to restrain the market. For instance, according to the Substance Abuse and Mental Health Services Administration report 2020, An estimated 353,000 people in Unites States used or misused all three CNS stimulants in the past year.
To understand geography trends, Download Sample Report
The Central Nervous System (CNS) Stimulant Drugs market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Ironshore Pharmaceuticals Inc., Noven Therapeutics, LLC., Azurity Pharmaceuticals, Inc, Independence Pharmaceuticals, Janssen Pharmaceuticals, Inc., Novartis AG, Takeda Pharmaceutical Co. Ltd, Elite Pharmaceuticals Inc., Kempharm, Inc, and Adlon Therapeutics L.P
- In January 2021, Glenmark Pharma received the United States Food and Drug Administration (USFDA) approval for nervous system stimulant drug for Amphetamine Sulfate tablets in the strengths of 5 mg and 10 mg.
- In July 2021, Adlon Therapeutics received the United States Food and Drug Administration New Drug Application approval for Adhansia XR.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Central Nervous System Disorders
4.2.2 Increase in Geriatric Population
4.3 Market Restraints
4.3.1 The Numerous Side Effects of Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Poduct Type
5.1.3 Methylphenidate HCl
5.1.4 Other Product Type
5.2 By Application
5.2.1 Attention Deficit Hyperactivity Disorder (ADHD)
5.2.2 Sleeping Disorder
5.2.3 Other Applications
5.3.1 North America
188.8.131.52 United States
184.108.40.206 United Kingdom
220.127.116.11 Rest of Europe
18.104.22.168 South Korea
22.214.171.124 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
126.96.36.199 South Africa
188.8.131.52 Rest of Middle-East and Africa
5.3.5 South America
184.108.40.206 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Ironshore Pharmaceuticals Inc.
6.1.2 Noven Therapeutics, LLC.
6.1.3 Azurity Pharmaceuticals, Inc.
6.1.4 Independence Pharmaceuticals
6.1.5 Janssen Pharmaceuticals, Inc.
6.1.6 Novartis AG
6.1.7 Takeda Pharmaceutical Co. Ltd
6.1.8 Elite Pharmaceuticals Inc.
6.1.9 Kempharm, Inc.
6.1.10 Adlon Therapeutics L.P
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Central Nervous System (CNS) Stimulant Drugs Market market is studied from 2019 - 2027.
What is the growth rate of Global Central Nervous System (CNS) Stimulant Drugs Market ?
The Global Central Nervous System (CNS) Stimulant Drugs Market is growing at a CAGR of 4.3% over the next 5 years.
Which region has highest growth rate in Global Central Nervous System (CNS) Stimulant Drugs Market ?
Asia-Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Central Nervous System (CNS) Stimulant Drugs Market ?
North America holds highest share in 2021.
Who are the key players in Global Central Nervous System (CNS) Stimulant Drugs Market ?
Ironshore Pharmaceuticals Inc. , Novartis AG , Takeda Pharmaceutical Co. Ltd, Azurity Pharmaceuticals, Inc., Noven Therapeutics, LLC. are the major companies operating in Global Central Nervous System (CNS) Stimulant Drugs Market .